MX2018009225A - Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. - Google Patents
Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.Info
- Publication number
- MX2018009225A MX2018009225A MX2018009225A MX2018009225A MX2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A MX 2018009225 A MX2018009225 A MX 2018009225A
- Authority
- MX
- Mexico
- Prior art keywords
- vectors
- subject
- frameshift
- mutation
- disease
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 7
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 231100000221 frame shift mutation induction Toxicity 0.000 abstract 4
- 230000037433 frameshift Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010041986 DNA Vaccines Proteins 0.000 abstract 1
- 229940021995 DNA vaccine Drugs 0.000 abstract 1
- 241000186781 Listeria Species 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición de inmunoterapia personalizada para un sujeto que padece una enfermedad o trastorno, que incluye vectores de administración de vacuna terapéutica y a métodos para preparar la misma, que comprenden construcciones de expresión génica que expresan péptidos derivados de mutaciones de modificación del marco asociados con uno o más neoepítopos codificados por secuencias de ácido nucleico que comprenden por lo menos una mutación de modificación del marco, en donde la mutación de modificación del marco es específica del cáncer o tejido no sano del sujeto. El vector de distribución o administración de la presente invención incluye vectores bacterianos, o vectores virales, o vectores de vacuna peptídica; o vectores de vacuna de ADN que incluyen vectores bacterianos de Listeria que comprenden una o más proteínas de fusión, que comprenden uno o más péptidos derivados de mutaciones de modificación del marco, que contienen uno o más neoepítopos presentes en muestras biológicas portadoras de la enfermedad provenientes del sujeto. También se describen métodos para el uso de estas composiciones para inducir una respuesta inmunitaria contra la enfermedad o trastorno, incluyendo un tumor o cáncer, o una infección, en el sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662287871P | 2016-01-27 | 2016-01-27 | |
PCT/US2017/015403 WO2017132547A1 (en) | 2016-01-27 | 2017-01-27 | Personalized delivery vector-based immunotherapy and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009225A true MX2018009225A (es) | 2019-08-21 |
Family
ID=59398812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009225A MX2018009225A (es) | 2016-01-27 | 2017-01-27 | Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190032064A1 (es) |
EP (1) | EP3408395A4 (es) |
JP (1) | JP2019503186A (es) |
KR (1) | KR20180100443A (es) |
CN (1) | CN108884468A (es) |
AU (1) | AU2017211387A1 (es) |
CA (1) | CA3012829A1 (es) |
MA (1) | MA47398A (es) |
MX (1) | MX2018009225A (es) |
SG (1) | SG11201806392XA (es) |
WO (1) | WO2017132547A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | ADJUVANZIA ON LISTERIA BASE |
SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
WO2015126921A1 (en) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
WO2015164121A1 (en) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
MA41644A (fr) * | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
MX2020003100A (es) | 2017-09-19 | 2020-08-20 | Advaxis Inc | Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria. |
SG11202008539YA (en) * | 2018-03-06 | 2020-10-29 | Precigen Inc | Human papillomavirus vaccines and uses of the same |
CN110408634B (zh) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
CN111334521B (zh) * | 2018-12-18 | 2022-02-18 | 上海若泰医药科技有限公司 | 一种提高非整合减毒李斯特菌外源抗原蛋白表达的方法 |
CA3131824A1 (en) * | 2019-03-11 | 2020-09-17 | Birgitte Rono | Nucleic acid vaccination using neo-epitope encoding constructs |
CA3161242A1 (en) * | 2019-12-18 | 2021-06-24 | Birgitte Rono | Nucleic acid vaccination using neo-epitope encoding constructs |
CA3178487A1 (en) * | 2020-05-14 | 2021-11-18 | Daniel Omar FRIMANNSSON | Polynucleotides comprising an antigenic payload |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
WO2009143085A1 (en) * | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comprising prfa*mutant listeria and methods of use thereof |
WO2015126921A1 (en) * | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
-
2017
- 2017-01-27 CN CN201780020675.4A patent/CN108884468A/zh active Pending
- 2017-01-27 US US16/073,194 patent/US20190032064A1/en not_active Abandoned
- 2017-01-27 AU AU2017211387A patent/AU2017211387A1/en not_active Abandoned
- 2017-01-27 EP EP17744997.2A patent/EP3408395A4/en not_active Withdrawn
- 2017-01-27 KR KR1020187024523A patent/KR20180100443A/ko unknown
- 2017-01-27 WO PCT/US2017/015403 patent/WO2017132547A1/en active Application Filing
- 2017-01-27 MX MX2018009225A patent/MX2018009225A/es unknown
- 2017-01-27 MA MA047398A patent/MA47398A/fr unknown
- 2017-01-27 SG SG11201806392XA patent/SG11201806392XA/en unknown
- 2017-01-27 CA CA3012829A patent/CA3012829A1/en not_active Abandoned
- 2017-01-27 JP JP2018539059A patent/JP2019503186A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190032064A1 (en) | 2019-01-31 |
CA3012829A1 (en) | 2017-08-03 |
KR20180100443A (ko) | 2018-09-10 |
CN108884468A (zh) | 2018-11-23 |
SG11201806392XA (en) | 2018-08-30 |
JP2019503186A (ja) | 2019-02-07 |
AU2017211387A1 (en) | 2018-08-16 |
EP3408395A1 (en) | 2018-12-05 |
EP3408395A4 (en) | 2019-12-11 |
MA47398A (fr) | 2019-12-11 |
WO2017132547A1 (en) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018009225A (es) | Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. | |
MX2017015149A (es) | Inmunoterapia personalizada basada en vectores de suministro y usos de esta. | |
MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
EP3424524A3 (en) | Cancer rna-vaccine | |
CR20190594A (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
EP4032544A3 (en) | Novel t cell receptors and immune therapy using the same | |
CA3045233A1 (en) | Novel t cell receptors and immune therapy using the same | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
CN107072184A (zh) | 嵌合抗原受体 | |
PH12020551039A1 (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
JP2018528237A5 (es) | ||
WO2008084115A3 (en) | Lactococcus promoters and uses thereof | |
MX2012005864A (es) | Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas. | |
JP2014510519A5 (es) | ||
MX2018010850A (es) | Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos. | |
ES2605020T3 (es) | Composición de ADN para inducir una respuesta inmunitaria contra macrófagos asociados a tumor | |
NZ760008A (en) | Uti fusion proteins | |
PH12015501467A1 (en) | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof | |
NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
CN103360497A (zh) | 一种新型抗肿瘤融合蛋白疫苗及其制备方法和应用 |